Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, July 11th.
Several other equities research analysts also recently weighed in on ENTA. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price objective on the stock in a report on Tuesday, July 11th. Finally, ValuEngine raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Enanta Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $33.00.
Enanta Pharmaceuticals (NASDAQ ENTA) opened at 39.23 on Tuesday. Enanta Pharmaceuticals has a 1-year low of $21.00 and a 1-year high of $41.20. The firm’s market cap is $748.63 million. The firm has a 50-day moving average price of $36.29 and a 200-day moving average price of $32.18.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 4.94% and a negative net margin of 28.68%. The company had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. During the same quarter last year, the company posted ($0.06) EPS. The company’s revenue for the quarter was down 46.3% compared to the same quarter last year. On average, analysts expect that Enanta Pharmaceuticals will post $0.46 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Enanta Pharmaceuticals, Inc. (ENTA) Downgraded by BidaskClub to Hold” was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/markets/enanta-pharmaceuticals-inc-enta-downgraded-by-bidaskclub-updated-updated-updated/1198293.html.
Several institutional investors have recently added to or reduced their stakes in the stock. GAM Holding AG acquired a new position in Enanta Pharmaceuticals during the second quarter valued at about $108,000. Virginia Retirement Systems ET AL increased its position in Enanta Pharmaceuticals by 2.2% in the second quarter. Virginia Retirement Systems ET AL now owns 65,900 shares of the biotechnology company’s stock valued at $2,371,000 after buying an additional 1,400 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,702 shares during the last quarter. Legal & General Group Plc increased its position in Enanta Pharmaceuticals by 9.0% in the second quarter. Legal & General Group Plc now owns 25,166 shares of the biotechnology company’s stock valued at $906,000 after buying an additional 2,080 shares during the last quarter. Finally, Alps Advisors Inc. increased its position in Enanta Pharmaceuticals by 4.9% in the second quarter. Alps Advisors Inc. now owns 17,182 shares of the biotechnology company’s stock valued at $618,000 after buying an additional 806 shares during the last quarter. 65.95% of the stock is owned by institutional investors.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.